Michael Singer, MD; Anthony DeFino , 2025-05-16 14:00:00
FORT LAUDERDALE, Fla. — In this Healio Video Perspective, Michael A. Singer, MD, discusses promising results for migaldendranib for the treatment of wet age-related macular degeneration and diabetic macular edema.
The subcutaneous injection is a tyrosine kinase inhibitor designed to block all forms of VEGF, Singer explained at the Retina World Congress. A study investigated migaldendranib (Ashvattha Therapeutics) given monthly and every 2 weeks.
“This is the first potential at-home monthly therapy that can be used either alone or in combination with intravitreal anti-VEGF medicines to control these diseases that we are having a lot of problems being able to keep under control. It will hopefully decrease the need for monthly visits and increase compliance,” Singer said.
Sources/Disclosures
Collapse
Singer M. Emerging data on anti-angiogenetic nanomedicine (migaldendranib MGB/D-4517.2) for AMD and DME. Presented at: Retina World Congress; May 8-11, 2025; Fort Lauderdale, Florida.
Disclosures:
Singer reports no relevant financial disclosures.
